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Abstract 
Myeloid sarcoma, which sometimes accompanies recurrent systemic leukemia, is a rare 
manifestation of congenital leukemia. We describe the case of a 1-month-old Japanese girl 
with myeloid sarcoma, who did not fulfill the criteria of systemic leukemia. The physical 
examination revealed a bruise-like plaque on the right side of her chest. Histopathologically, 
there were CD4+ CD56– CD68+ atypical large lymphocytes densely infiltrating the upper 
dermis and the subcutaneous tissue. Biopsy specimens from bone marrow contained only 
3.4% of blast cells, showing an abnormality of the mixed-lineage leukemia gene. The skin 
lesions disappeared 10 days after chemotherapy, and there was no recurrence for one and a 
half years. 
 
Introduction 
Myeloid sarcoma (MS), or granulocytic sarcoma, is a lesion characterized by the 
presence of one or more tumor masses consisting of myeloblasts or immature myeloid 
cells at sites other than the bone marrow, with the skin being the site of predilection. 
The recent World Health Organization (WHO) classification has proposed the 
subdivision of MS into several histotypes, but the exact incidence of this disease has not 
been established yet [1]. Because MS expresses various differentiation markers and is 
subdivided immunohistochemically into several categories, immunophenotyping is 
essential to avoid misdiagnosis and inappropriate treatment [2, 3]. In addition, MS is 
associated with a variety of chromosomal abnormalities as well as mixed-lineage 
leukemia (MLL) rearrangements. 
In this report, we describe a case of MS with multifocal bruise-like plaques over the 
trunk and extremities that showed abnormalities of the MLL gene and chromosomes. Case Rep Dermatol 2011;3:219–222 
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Case Report 
A 1-month-old Japanese girl presented to our outpatient clinic with an asymptomatic plaque on 
her chest. At her initial visit, physical examination revealed a 13 × 16 mm, red-violaceous, bruise-like 
plaque on the right side of her chest (fig. 1). One week after her arrival, disseminated bruise-like 
purpura was detected on her extremities. A biopsy specimen from the chest revealed atypical cells 
densely infiltrating the subcutaneous tissue through the dermis (fig. 2a). Infiltrating cells were 
medium-sized, with a high nuclear/cytoplasmic ratio and prominent nucleoli (fig. 2b). 
Immunohistochemical staining revealed that these infiltrating cells mainly consisted of CD4+ cells 
(fig. 2c), were diffusely CD68 positive (fig. 2d) and CD56 negative. Infiltrating cells were also negative 
for CD3, CD5, CD8, CD10, CD20, CD34, CD45, CD79α, neutrophil elastase, and myeloperoxidase. The 
Ki67 score was approximately 80%. Biopsy specimens from bone marrow contained only 3.4% blast 
cells; however, biopsies of the skin showed abnormalities in the MLL gene. Moreover, the division 
inside the MLL gene area (11q23) was detected in about 84% of counted cells by fluorescence in situ 
hybridization. Based on the above data, we diagnosed this patient as having MS with 
monoblastic/monocytic differentiation [1]. The patient was treated with the so-called MLL99 regimen 
consisting of etoposide, cytarabine, mitoxantrone, idarubicin, methotrexate and hydrocortisone. The 
skin lesions disappeared 10 days after the administration of MLL99, and there was no evidence of 
recurrence for one and a half years. 
Discussion 
MS usually presents as a single mass, although cases of MS with multiple skin lesions 
have also been reported [3]. In this report, we present a case of MS with multifocal 
bruise-like plaques over the trunk and extremities. 
MS is a rare condition characterized by the occurrence of one or more tumor masses 
consisting of immature myeloid cells presenting at an extramedullary site. It may 
develop de novo or concurrently with acute myeloid leukemia (AML), 
myeloproliferative disorder (MPD) or myelodysplastic syndrome (MDS) [3, 4]. Indeed, 
Pileri et al. [3] reviewed 92 cases of MS and suggested that 25% of the patients 
developed de novo disease, and the other cases had AML, MPD or MDS simultaneously 
(32%) or previously (35%). 
As for the prognosis of this disorder, the presence of MPD, MDS or AML is reported 
to be a negative prognostic factor [3, 5]. By contrast, de novo MS has been described as 
sensitive to radiotherapy and/or chemotherapy, with possible prolonged survival. 
However, recent studies suggest that either highly specific drugs or aggressive 
regimens should also be applied to de novo MS, if the aim is to achieve stable remission 
and cure. In our present case, we administered the MLL99 regimen and achieved 
complete remission for one and a half years. Though there is no definitive consensus 
concerning the optimal treatment for MS, our present case suggests that intensive 
chemotherapy is necessary to induce complete remission of MS. 
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Fig. 1. Red-violaceous bruise-like plaque, 13 × 16 mm in size, on the right side of the chest. 
 
 
 
Fig. 2. Atypical cells densely infiltrating the dermis and the subcutaneous tissue (a). Infiltrating cells 
were medium-sized, with a high nuclear/cytoplasmic ratio and prominent nucleoli (b). 
Immunohistochemical staining for CD4 (c) and CD68 (d). Original manifestation ×50 (a, c, d) and 
×400 (b). 
 Case Rep Dermatol 2011;3:219–222 
DOI: 10.1159/000333206 
Published online: 
September 30, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–6567 
www.karger.com/cde 
 
 
 
222 
References 
1  Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW: WHO Classification 
of Tumours of Haematopoietic and Lymphoid Tissues, ed 4. Lyon, IARC, 2008. 
2  Nakagawa S, Tagami H, Ichinohasama R, Aiba S: Rapid growing cobblestone-like nodules as a 
manifestation of myeloid sarcoma. Acta Derm Venereol 2008;88:633–634. 
3  Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, et al: Myeloid sarcoma: clinico-pathologic, phenotypic 
and cytogenetic analysis of 92 adults patients. Leukemia 2007;21:340–350. 
4  Campidelli C, Agostinelli C, Stitson R, Pileri SA: Myeloid sarcoma: extramedullary manifestation of 
myeloid disorders. Am J Clin Pathol 2009;132:426–437. 
5  Magro CM, Porcu P, Schaefer J, Erter JW, Furman RR, Shitabata PK, Crowson AN: Cutaneous CD4+ CD56+ 
hematologic malignancies. J Am Acad Dermatol 2010;63:292–308. 